Biotech
AstraZeneca buys partner Omniose for bacterial vaccine technology
By Nick Paul Taylor
Nov 10, 2026 10:16am
AstraZeneca has made Omniose a wholly owned subsidiary within its infectious disease unit. (CFOTO/Future Publishing/Getty Images)
AstraZeneca has acquired vaccine bioconjugation specialist Omniose, securing technology and expertise that could boost its efforts to protect people from bacterial threats.
Omniose partnered with AstraZeneca in January 2024. Under the three-year pact, the collaborators worked on vaccines against bacterial pathogens, including multidrug-resistant “superbugs.” The partnership built on evidence that Omniose had developed technology to unlock the potential of conjugate vaccines.
With the alliance drawing to a close, AstraZeneca has made Omniose a wholly owned subsidiary within its infectious disease unit.
“Omniose’s bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines…